why does nobody talk about state board
Question in the title, detail here: why does nobody talk about state board.
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
Would rather be corrected in public than confident in private.
best — the order this archive was captured in
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
ask which facility, then ask for their testing
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
Cosigning the beyond-use date question. What it is based on tells you whether anybody has done stability work.
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
Who is the prescriber, and are they the same organisation as the pharmacy?
salt forms are the recurring argument and the answer is boring
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
the pharmacy and the prescriber are two separate questions
compounded is not generic, there is no equivalence claim
ask what the beyond-use date is based on
do not assume the concentration matches the branded product
That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.
That figure is the starting material purity, not the finished preparation potency. Two different tests.
503A is patient-specific, 503B is outsourcing facility, they are not the same thing
Switched between two compounded preparations and the concentration on the label was different. Redid the arithmetic on paper before drawing anything.
potency testing on the finished preparation is the thing to ask for